TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01409993
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil 25 mg by mouth three times a day for three months
Study: NCT01127295
Drug: Tamoxifen, Letrozole, Anastrozole or Exemestane
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/day during 5 years Létrozole 2.5 mg/day during 5 years Anastrozole 1 mg/day during 5 years Exémestane 25 mg/day during 5 years
Study: NCT00044486
Drug: Posaconazole oral suspension
Normalized name: Posaconazole Oral Suspension
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01492699
Drug: PRX-03140
Normalized name: PRX-03140
DrugBank: PRX-03140 (DB05596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg PRX-03140 capsules once daily for 2 weeks. After 2 weeks, the dose will increase to 100mg PRX-03140 once daily for 10 weeks.
Study: NCT01372449
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Memantine will be initiated at 3 mg. The dose will be increased every week by 3 mg for a maximum of 12mg for subjects weighing ≥ 60kg, 9mg for subjects weighing ≥ 40 kg but \<60 kg, and 6 mg for subjects weighing ≥ 20 kg but \< 40kg.
Study: NCT00453232
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00453232
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03552627
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medical Oxygen
Study: NCT02448004
Drug: JNJ-63623872
Normalized name: JNJ-63623872
DrugBank: Pimodivir (DB14974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single 600-mg dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
Study: NCT00979017
Drug: Avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avastin, by intravenous infusion, 10 mg/kg every 14 days
Study: NCT00979017
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral temozolomide at 200 mg/m2 daily for 5 days
Study: NCT00979017
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan, by intravenous infusion, every other week (dose dependent upon if taking enzyme-inducing anti-epileptic drugs or if a blood test indicates the patient has the UGT 1A1 polymorphism)
Study: NCT00185354
Drug: SH P00331N
Normalized name: Glutathione-SH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug amount per patch: 0.6 mg EE2 + 6 mg NGM
Study: NCT00410449
Drug: Alpha tocopherol
Normalized name: alpha tocopherol
DrugBank: Tocopherol (DB11251)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03289741
Drug: Octreotide
Normalized name: Octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive three monthly injections every 28 (+/- 3) days. Octreotide LAR for 3 injections followed by lanreotide for 3 injections
Study: NCT03289741
Drug: LAR Lanreotide
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive three monthly injections every 28 (+/- 3) days. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
Study: NCT00002718
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002718
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002718
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00862654
Drug: clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)
Normalized name: clobetasol propionate Medicated Shampoo
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Association: clobetasol propionate shampoo \& ketoconazole shampoo
Study: NCT00862654
Drug: clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week)
Normalized name: clobetasol propionate Medicated Shampoo
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Association: clobetasol propionate shampoo \& ketoconazole shampoo
Study: NCT00862654
Drug: clobetasol propionate shampoo (2/week)
Normalized name: clobetasol propionate Medicated Shampoo
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Monotherapy with clobetasol propionate shampoo
Study: NCT00862654
Drug: ketoconazole shampoo (2/week)
Normalized name: ketoconazole Medicated Shampoo
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monotherpay ketoconazole shampoo (2/week)
Study: NCT00226967
Drug: Sandostatin
Normalized name: Sandostatin
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Calculated per patient
Study: NCT03451500
Drug: carbidopa-levodopa
Normalized name: Carbidopa-Levodopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See previous
Study: NCT03258697
Drug: Levobupivacaine Hydrochloride
Normalized name: Levobupivacaine Hydrochloride
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Different way of LevoBupivacaine injection
Study: NCT00356395
Drug: ramipril, candesartan
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00735670
Drug: Venlafaxine HCl
Normalized name: venlafaxine HCl
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose is 37.5 mg and ending dose is 150 mg at 13 weeks. From weeks 13 to 26 subjects no longer will receive the drug
Study: NCT00643357
Drug: 50% Oxygen/50% Nitrous oxide premix (KALINOX 170 bar)
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gaz flow between 4 to 15 L/min inhalation between 15 to 60 minutes
Study: NCT00505895
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm 1 = 140 mg/m\^2 intravenous over 20 Minutes on Day -1; Arm 2 = 100 mg/m\^2 intravenous over 20 Minutes on Day -1.
Study: NCT00505895
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m\^2 intravenous daily over 30 Minutes for 4 Days (Beginning Day -4).
Study: NCT00505895
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 intravenous on Day -5, +2 +9 and +16.
Study: NCT03173612
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Primary AML includes CBF-AML and non-CBF-AML. Children with a WBC (white blood cell) lower than 4,000/μL and low proliferative bone marrow at diagnosis are treated with CAG. Other children are treated with MAE. The rescue regimen for children who showed M3 marrow after MAE or CAG is IAE. Consolidation therapy consisted of four (for CBF-AML) or five (for non-CBF-AML) courses, and triplein trathecal therapy is given as a part of each course. After the second course of therapy, CBF-AML are stratified into two risk groups, while non-CBF-AML patients in remission are stratified into three risk groups.Consolidation regimen for CBF-AML includes IA, MA, IA, MA. Dasatinib is used in CBF-AML as a part of consolidation therapy. Consolidation regimen for non-CBF-AML includes IAE, MAE, EA, IAE, EA or MAE.
Study: NCT04077736
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose interleukin-2 injected subcutaneously, at a dose of 1 million IU five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
Study: NCT01300364
Drug: Reboxetine
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8mg/day.
Study: NCT01300364
Drug: citalopram (SSRI)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mg/day
Study: NCT02138396
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone is provided as a 50 mg tablet before and after product dosing to minimize unacceptable adverse effects of fentanyl.
Study: NCT00546286
Drug: dorzolamide hydrochloride (+) timolol maleate
Normalized name: dorzolamide / timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combination treatment of dorzolamide HCl (2%)/ timolol maleate (0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients who achieve target IOP at 6 weeks, dorzolamide/timolol is continued for another 6 weeks.
Study: NCT03071380
Drug: Xarelto
Normalized name: Xarelto
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 tablet contains 10 mg rivaroxaban
Study: NCT00181935
Drug: risperidone (Risperdal)
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00181935
Drug: olanzapine (Zyprexa)
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03404635
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban as standard of care for VTE
Study: NCT03404635
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban as standard of care for VTE
Study: NCT03479216
Drug: Precedex
Normalized name: Precedex
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.
Study: NCT03479216
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.
Study: NCT00525408
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapeutic agent
Study: NCT03846219
Drug: IMU-838 (30 mg/day)
Normalized name: LACTOBACILLUS HELVETICUS 1.50 g in 150 mL / RICE BRAN 1.50 g in 150 mL TOPICAL AEROSOL, FOAM [IMU]
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 15 mg tablet IMU-838 daily) and then start taking the full assigned dose from Day 7 onwards (two 15 mg tablets IMU-838 once daily).~* Optional extended treatment period (optional): Participants who were re-randomized to a 30 mg/day dose will take the full assigned dose which consists of two 15 mg tablets IMU-838 once daily.
Study: NCT03846219
Drug: IMU-838 (45 mg/day)
Normalized name: LACTOBACILLUS HELVETICUS 1.50 g in 150 mL / RICE BRAN 1.50 g in 150 mL TOPICAL AEROSOL, FOAM [IMU]
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 22.5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 22.5 mg tablets once daily).~* Optional extended treatment period (optional): Participants who were re-randomized to a 45 mg/day dose will take the full assigned dose of two 22.5 mg tablets IMU-838 once daily.
Study: NCT03846219
Drug: IMU-838 (10 mg/day)
Normalized name: LACTOBACILLUS HELVETICUS 1.50 g in 150 mL / RICE BRAN 1.50 g in 150 mL TOPICAL AEROSOL, FOAM [IMU]
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Main treatment period for Cohort 2: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 5 mg tablets once daily).~* Optional extended treatment period (not applicable to Cohort 2): IMU-838 10 mg/day not applicable.
Study: NCT03073408
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Closed loop control for propofol administration guided by the BIS.
Study: NCT03073408
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual control group: Propofol administration adjusted manually.
Study: NCT04126031
Drug: Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single intravenous infusion of ceftazidime-avibactam over 2 hours
Study: NCT04126031
Drug: Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple intravenous infusions of ceftazidime-avibactam over 2 hours, repeated every 8 hours up to 14 days
Study: NCT04132648
Drug: Curcumin
Normalized name: Curcumin
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplement one time at 2,000 mg
Study: NCT02999100
Drug: IH Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin will be supplied as colourless and clear hard capsule with powder blend for inhalation with unit dose strength 400 mcg and 200 mcg. It will be administered using ROTAHALER dry powder inhaler (DPI).
Study: NCT02999100
Drug: IM Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin will be supplied for solution for infusion in 1ml ampoule containing colourless and clear sterile solution with unit dose strength 5 I.U./mL, or 10 I.U./mL for IM administration
Study: NCT02999100
Drug: IV Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin will be supplied as solution for infusion in 1ml ampoule containing colourless and clear sterile solution to be administered as a 30-second IV bolus with unit dose strength 5 I.U./mL, or 10 I.U./mL.
Study: NCT01742533
Drug: Hormone Replacement Therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04066530
Drug: AD-203
Normalized name: ODM-203
DrugBank: ODM-203 (DB16843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD-203 administered two times daily for two weeks
Study: NCT01344252
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We will made anesthesia with topical lidocaine and compared with subtenon anesthesia
Study: NCT01705795
Drug: Mepolizumab (a-IL-5 antibody)
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 750mg mepolizumab four times over four months
Study: NCT02244281
Drug: tamsulosin hydrochloride
Normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00749450
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02664181
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be given at 3mg/kg by IV every two weeks until progression
Study: NCT02664181
Drug: oral decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral decitabine \~0.2 mg/kg 60 minutes after the THU, twice weekly on consecutive days.
Study: NCT02664181
Drug: Tetrahydrouridine
Normalized name: Tetrahydrouridine
DrugBank: Tetrahydrouridine (DB12484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral THU \~10 mg/kg twice weekly on consecutive days
Study: NCT01002924
Drug: EC145
Normalized name: Etirinotecan pegol
DrugBank: Etirinotecan pegol (DB14951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC145 will be administered intravenously at a dose of 2.5 mg. Dosing will occur on Monday, Wednesday, and Friday of weeks 1 and 3 of each 4-week cycle. No therapy will be administered during weeks 2 and 4.
Study: NCT02962518
Drug: Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients received intra-lesional injections of tiamcinolone 10mg/ml every 4 to 6 weeks for 6 months.
Study: NCT02251600
Drug: Deflazacort
Normalized name: Deflazacort
DrugBank: Deflazacort (DB11921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral deflazacort administered once daily at 0.9 mg/kg for eight days
Study: NCT01311687
Drug: pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg pomalidomide capsules administered orally
Study: NCT01311687
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg dexamethasone (or 20 mg for participants \> 75 years of age) tablets administered orally
Study: NCT00248261
Drug: ziprasidone, sertraline
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01736592
Drug: Long term follow up in all patients who received SAR422459 in previous study TDU13583
Normalized name: benzethonium
DrugBank: SAR422459 (DB17908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blood draw for the laboratory assessment
Study: NCT04247373
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: According to previous patient's response, the investigators will allocate the concentration of ropivacaine of next patient during Co2 insufflation. And, for this allocation of concentration of ropivacaine the investigators use biased coin design up-and-down method.
Study: NCT03098160
Drug: Evofosfamide
Normalized name: Evofosfamide
DrugBank: Evofosfamide (DB06091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.
Study: NCT03098160
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.
Study: NCT00055731
Drug: bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00055731
Drug: Goserelin Acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00055731
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00055731
Drug: Estramustine phosphate sodium
Normalized name: Estramustine Phosphate Sodium
DrugBank: Estramustine (DB01196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03270839
Drug: Kwells
Normalized name: Kwell
DrugBank: Lindane (DB00431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motion sickness drug
Study: NCT00124748
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib is packaged in bottles as 100mg and 400mg tablets
Study: NCT03942601
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1
Study: NCT03942601
Drug: Temsirolimus and dexamethasone sodium phosphate
Normalized name: Temsirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2
Study: NCT00948155
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention Drug (Varenicline (Chantix) will be administered in standard dosing in pill format: 0.5 mg days 1-3; 0.5 mg bid daily days 4-7; 1.0 mg bid daily days 8-21.
Study: NCT03648229
Drug: Latanoprost ophthalmic solution
Normalized name: Latanoprost Ophthalmic Solution
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prostaglandin analogue topical ophthalmic medication for reduction of intraocular pressure
Study: NCT03648229
Drug: Timolol ophthalmic solution
Normalized name: timolol Ophthalmic Solution
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol ophthalmic solution 0.5% for reduction of intraocular pressure
Study: NCT03970577
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two injections of Rituximab (375mg/m2) separated by one week (one at time of randomization and the other one week after) and definitive withdrawal of steroid at the time of second injection of Rituximab (for a total steroids exposure of 9 weeks)
Study: NCT03970577
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: exclusive oral steroid therapy (progressively tapered with the same procedure for all patients) for a total exposure of 24 weeks (taking into account the initial oral steroid therapy administered during 8 weeks in addition with the oral steroid treatment given after randomization). Each patient will be followed up until 18 months after randomization.
Study: NCT03315078
Drug: Palifermin
Normalized name: palifermin
DrugBank: Palifermin (DB00039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by IV infusion at a dose of 60 mg/kg/day
Study: NCT03315078
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by IV infusion at a dose of approximately 3 mg/kg per day
Study: NCT00425321
Drug: RWJ-445380 100 mg
Normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-445380 100 mg once daily for up to 12 weeks
Study: NCT00425321
Drug: RWJ-445380 200 mg
Normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-445380 200 mg once daily for up to 12 weeks
Study: NCT00425321
Drug: RWJ-445380 300 mg
Normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-445380 300 mg once daily for up to 12 weeks
Study: NCT02749617
Drug: apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2.5 mg PO BID
Study: NCT02561117
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration once daily